Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

CEST MR-Fingerprinting: Practical considerations and insights for acquisition schedule design and improved reconstruction.

Perlman O, Herz K, Zaiss M, Cohen O, Rosen MS, Farrar CT.

Magn Reson Med. 2019 Aug 9. doi: 10.1002/mrm.27937. [Epub ahead of print]

PMID:
31400034
2.

A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging.

Kuruppu D, Bhere D, Farrar CT, Shah K, Brownell AL, Tanabe KK.

Cancer Gene Ther. 2019 May;26(5-6):145-156. doi: 10.1038/s41417-018-0060-z. Epub 2018 Nov 13.

PMID:
30420717
3.

Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist.

Erstad DJ, Farrar CT, Ghoshal S, Masia R, Ferreira DS, Chen YI, Choi JK, Wei L, Waghorn PA, Rotile NJ, Tu C, Graham-O'Regan KA, Sojoodi M, Li S, Li Y, Wang G, Corey KE, Or YS, Jiang L, Tanabe KK, Caravan P, Fuchs BC.

Hepatol Commun. 2018 May 21;2(7):821-835. doi: 10.1002/hep4.1193. eCollection 2018 Jul.

4.

Rapid and quantitative chemical exchange saturation transfer (CEST) imaging with magnetic resonance fingerprinting (MRF).

Cohen O, Huang S, McMahon MT, Rosen MS, Farrar CT.

Magn Reson Med. 2018 Dec;80(6):2449-2463. doi: 10.1002/mrm.27221. Epub 2018 May 13.

PMID:
29756286
5.

CM-101: Type I Collagen-targeted MR Imaging Probe for Detection of Liver Fibrosis.

Farrar CT, Gale EM, Kennan R, Ramsay I, Masia R, Arora G, Looby K, Wei L, Kalpathy-Cramer J, Bunzel MM, Zhang C, Zhu Y, Akiyama TE, Klimas M, Pinto S, Diyabalanage H, Tanabe KK, Humblet V, Fuchs BC, Caravan P.

Radiology. 2018 May;287(2):581-589. doi: 10.1148/radiol.2017170595. Epub 2017 Nov 20.

6.

Evaluation of antitumor activity and cardiac toxicity of a bone-targeted ph-sensitive liposomal formulation in a bone metastasis tumor model in mice.

Dos Santos Ferreira D, Jesus de Oliveira Pinto BL, Kumar V, Cardoso VN, Fernandes SO, Souza CM, Cassali GD, Moore A, Sosnovik DE, Farrar CT, Leite EA, Alves RJ, de Oliveira MC, Guimarães AR, Caravan P.

Nanomedicine. 2017 Jul;13(5):1693-1701. doi: 10.1016/j.nano.2017.03.005. Epub 2017 Mar 23.

7.

Exceedingly small iron oxide nanoparticles as positive MRI contrast agents.

Wei H, Bruns OT, Kaul MG, Hansen EC, Barch M, Wiśniowska A, Chen O, Chen Y, Li N, Okada S, Cordero JM, Heine M, Farrar CT, Montana DM, Adam G, Ittrich H, Jasanoff A, Nielsen P, Bawendi MG.

Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2325-2330. doi: 10.1073/pnas.1620145114. Epub 2017 Feb 13.

8.

Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model.

Zhu B, Wei L, Rotile N, Day H, Rietz T, Farrar CT, Lauwers GY, Tanabe KK, Rosen B, Fuchs BC, Caravan P.

Hepatology. 2017 Mar;65(3):1015-1025. doi: 10.1002/hep.28930. Epub 2016 Dec 31.

9.

A Janus Chelator Enables Biochemically Responsive MRI Contrast with Exceptional Dynamic Range.

Gale EM, Jones CM, Ramsay I, Farrar CT, Caravan P.

J Am Chem Soc. 2016 Dec 14;138(49):15861-15864. Epub 2016 Dec 2.

10.

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.

Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4470-5. doi: 10.1073/pnas.1525349113. Epub 2016 Apr 4.

11.

3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model.

Farrar CT, DePeralta DK, Day H, Rietz TA, Wei L, Lauwers GY, Keil B, Subramaniam A, Sinskey AJ, Tanabe KK, Fuchs BC, Caravan P.

J Hepatol. 2015 Sep;63(3):689-96. doi: 10.1016/j.jhep.2015.04.029. Epub 2015 May 25.

12.

Establishing the Lysine-rich Protein CEST Reporter Gene as a CEST MR Imaging Detector for Oncolytic Virotherapy.

Farrar CT, Buhrman JS, Liu G, Kleijn A, Lamfers ML, McMahon MT, Gilad AA, Fulci G.

Radiology. 2015 Jun;275(3):746-54. doi: 10.1148/radiol.14140251. Epub 2015 Feb 13.

13.

Magneto-fluorescent core-shell supernanoparticles.

Chen O, Riedemann L, Etoc F, Herrmann H, Coppey M, Barch M, Farrar CT, Zhao J, Bruns OT, Wei H, Guo P, Cui J, Jensen R, Chen Y, Harris DK, Cordero JM, Wang Z, Jasanoff A, Fukumura D, Reimer R, Dahan M, Jain RK, Bawendi MG.

Nat Commun. 2014 Oct 9;5:5093. doi: 10.1038/ncomms6093.

14.

Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

Emblem KE, Farrar CT, Gerstner ER, Batchelor TT, Borra RJ, Rosen BR, Sorensen AG, Jain RK.

Nat Rev Clin Oncol. 2014 Oct;11(10):566-84. doi: 10.1038/nrclinonc.2014.126. Epub 2014 Aug 12. Review.

15.

RNA aptamer probes as optical imaging agents for the detection of amyloid plaques.

Farrar CT, William CM, Hudry E, Hashimoto T, Hyman BT.

PLoS One. 2014 Feb 26;9(2):e89901. doi: 10.1371/journal.pone.0089901. eCollection 2014.

16.

Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy.

Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG.

Nat Med. 2013 Sep;19(9):1178-83. doi: 10.1038/nm.3289. Epub 2013 Aug 18.

17.

Cerebral blood volume affects blood-brain barrier integrity in an acute transient stroke model.

Huang S, Kim JK, Atochin DN, Farrar CT, Huang PL, Suh JY, Kwon SJ, Shim WH, Cho H, Cho G, Kim YR.

J Cereb Blood Flow Metab. 2013 Jun;33(6):898-905. doi: 10.1038/jcbfm.2013.27. Epub 2013 Mar 6.

18.

Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.

Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK.

Cell. 2013 Feb 28;152(5):1065-76. doi: 10.1016/j.cell.2013.01.036.

19.

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.

Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S, Snuderl M, Lussiez A, Hiddingh L, Mahmood S, Tannous BA, Eichler AF, Fukumura D, Engelman JA, Jain RK.

Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3119-27. doi: 10.1073/pnas.1216078109. Epub 2012 Oct 15.

20.

Dynamic monitoring of blood-brain barrier integrity using water exchange index (WEI) during mannitol and CO2 challenges in mouse brain.

Huang S, Farrar CT, Dai G, Kwon SJ, Bogdanov AA Jr, Rosen BR, Kim YR.

NMR Biomed. 2013 Apr;26(4):376-85. doi: 10.1002/nbm.2871. Epub 2012 Oct 11.

21.

Molecular imaging of fibrin in a breast cancer xenograft mouse model.

Uppal R, Medarova Z, Farrar CT, Dai G, Moore A, Caravan P.

Invest Radiol. 2012 Oct;47(10):553-8. doi: 10.1097/RLI.0b013e31825dddfb.

22.

Dynamic nuclear polarization at 9T using a novel 250 GHz gyrotron microwave source. 2003.

Bajaj VS, Farrar CT, Hornstein MK, Mastovsky I, Vieregg J, Bryant J, Eléna B, Kreischer KE, Temkin RJ, Griffin RG.

J Magn Reson. 2011 Dec;213(2):404-9. doi: 10.1016/j.jmr.2011.09.010. No abstract available.

PMID:
22152358
23.

Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging.

Koffie RM, Farrar CT, Saidi LJ, William CM, Hyman BT, Spires-Jones TL.

Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18837-42. doi: 10.1073/pnas.1111405108. Epub 2011 Nov 7.

24.

Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model.

Farrar CT, Kamoun WS, Ley CD, Kim YR, Catana C, Kwon SJ, Rosen BR, Jain RK, Sorensen AG.

PLoS One. 2011 Mar 3;6(3):e17228. doi: 10.1371/journal.pone.0017228.

25.

Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.

Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AM, Sorensen AG, Munn LL, Jain RK, Fukumura D.

Clin Cancer Res. 2010 Jul 15;16(14):3618-27. doi: 10.1158/1078-0432.CCR-09-3073. Epub 2010 May 25.

26.

In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model.

Farrar CT, Kamoun WS, Ley CD, Kim YR, Kwon SJ, Dai G, Rosen BR, di Tomaso E, Jain RK, Sorensen AG.

Neuro Oncol. 2010 Apr;12(4):341-50. doi: 10.1093/neuonc/nop032. Epub 2010 Jan 11.

27.

Target-specific contrast agents for magnetic resonance microscopy.

Blackwell ML, Farrar CT, Fischl B, Rosen BR.

Neuroimage. 2009 Jun;46(2):382-93.

28.

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK.

J Clin Oncol. 2009 May 20;27(15):2542-52. doi: 10.1200/JCO.2008.19.9356. Epub 2009 Mar 30.

29.

Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents.

Caravan P, Farrar CT, Frullano L, Uppal R.

Contrast Media Mol Imaging. 2009 Mar-Apr;4(2):89-100. doi: 10.1002/cmmi.267.

31.

Impact of field strength and iron oxide nanoparticle concentration on the linearity and diagnostic accuracy of off-resonance imaging.

Farrar CT, Dai G, Novikov M, Rosenzweig A, Weissleder R, Rosen BR, Sosnovik DE.

NMR Biomed. 2008 Jun;21(5):453-63.

32.

MR contrast probes that trace gene transcripts for cerebral ischemia in live animals.

Liu CH, Huang S, Cui J, Kim YR, Farrar CT, Moskowitz MA, Rosen BR, Liu PK.

FASEB J. 2007 Sep;21(11):3004-15. Epub 2007 May 3.

33.

Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults.

Fleischman A, Johnsen S, Systrom DM, Hrovat M, Farrar CT, Frontera W, Fitch K, Thomas BJ, Torriani M, Côté HC, Grinspoon SK.

Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1666-73. Epub 2007 Feb 6.

34.
35.

Dynamic nuclear polarization at 9T using a novel 250GHz gyrotron microwave source.

Bajaj VS, Farrar CT, Hornstein MK, Mastovsky I, Vieregg J, Bryant J, Eléna B, Kreischer KE, Temkin RJ, Griffin RG.

J Magn Reson. 2003 Feb;160(2):85-90.

36.

Electron spin resonance of TOAC labeled peptides: folding transitions and high frequency spectroscopy.

McNulty JC, Silapie JL, Carnevali M, Farrar CT, Griffin RG, Formaggio F, Crisma M, Toniolo C, Millhauser GL.

Biopolymers. 2000;55(6):479-85.

PMID:
11304675
37.
38.

High-frequency dynamic nuclear polarization in the nuclear rotating frame.

Farrar CT, Hall DA, Gerfen GJ, Rosay M, Ardenkjaer-Larsen JH, Griffin RG.

J Magn Reson. 2000 May;144(1):134-41.

PMID:
10783283
39.

Pulsed electron-nuclear double resonance (ENDOR) at 140 GHz.

Bennati M, Farrar CT, Bryant JA, Inati SJ, Weis V, Gerfen GJ, Riggs-Gelasco P, Stubbe J, Griffin RG.

J Magn Reson. 1999 Jun;138(2):232-43.

PMID:
10341127
40.
42.

High frequency (139.5 GHz) electron paramagnetic resonance spectroscopy of the GTP form of p21 ras with selective 17O labeling of threonine.

Halkides CJ, Bellew BF, Gerfen GJ, Farrar CT, Carter PH, Ruo B, Evans DA, Griffin RG, Singel DJ.

Biochemistry. 1996 Sep 17;35(37):12194-2200.

PMID:
8810927
43.

Characterization of the active site of p21 ras by electron spin-echo envelope modulation spectroscopy with selective labeling: comparisons between GDP and GTP forms.

Halkides CJ, Farrar CT, Larsen RG, Redfield AG, Singel DJ.

Biochemistry. 1994 Apr 5;33(13):4019-35. Erratum in: Biochemistry 1995 Oct 31;34(43):14270.

PMID:
8142406

Supplemental Content

Loading ...
Support Center